
ADMA Biologics faces securities fraud probe after 29% stock plunge over alleged channel stuffing.
ADMA Biologics is under investigation by law firm Bleichmar Fonti & Auld for potential securities fraud following a 29% stock drop. The plunge occurred after Culper Research accused the company of inflating 2025 revenue growth by 20% through channel ...
